-+ 0.00%
-+ 0.00%
-+ 0.00%

Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026

Benzinga·05/20/2026 20:16:06
Listen to the news

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study.